Patents by Inventor Shiqui Zhu

Shiqui Zhu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • T CELL RECEPTORS RECOGNIZING HLA-A1-RESTRICTED MAGE-A3
    Publication number: 20220195008
    Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a) melanoma antigen family A (MAGE A)-3 in the context of HLA-A1 or b) MAGE-A12 in the context of HLA-Cw7. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.
    Type: Application
    Filed: March 10, 2022
    Publication date: June 23, 2022
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Paul F. Robbins, Steven A. Rosenberg, Shiqui Zhu, Steven A. Feldman, Richard A. Morgan
  • T cell receptors recognizing HLA-A1- or HLA-CW7-restricted mage
    Patent number: 11306131
    Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a) melanoma antigen family A (MAGE A)-3 in the context of HLA-A1 or b) MAGE-A12 in the context of HLA-Cw7. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: April 19, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Paul F. Robbins, Steven A. Rosenberg, Shiqui Zhu, Steven A. Feldman, Richard A. Morgan
  • T CELL RECEPTORS RECOGNIZING HLA-A1- OR HLA-CW7-RESTRICTED MAGE
    Publication number: 20190016777
    Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a) melanoma antigen family A (MAGE A)-3 in the context of HLA-A1 or b) MAGE-A12 in the context of HLA-Cw7. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.
    Type: Application
    Filed: September 27, 2018
    Publication date: January 17, 2019
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Paul F. Robbins, Steven A. Rosenberg, Shiqui Zhu, Steven A. Feldman, Richard A. Morgan
  • T CELL RECEPTORS RECOGNIZING HLA-A1- OR HLA-CW7-RESTRICTED MAGE
    Publication number: 20140378389
    Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a) melanoma antigen family A (MAGE A)-3 in the context of HLA-A1 or b) MAGE-A12 in the context of HLA-Cw7. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.
    Type: Application
    Filed: September 11, 2012
    Publication date: December 25, 2014
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Paul F. Robbins, Steven A. Rosenberg, Shiqui Zhu, Steven A. Feldman, Richard A. Morgan